Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 10,301–10,400 of 10,906
COVID-19 mRNA vaccines: a prospective outlook from technological innovation to clinical practice
Ma, J., Chen, H., He, Y., Huang, Y., Duan, X., Liu, Q., Liu, Z., & Liu, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1757291 · Cited by 1
Keinan‐Boker, L., Fluss, R., Dichtiar, R., Rosenberg, A., Lassan, M. B., & Huppert, A. (2023) · Research Square · doi:10.21203/rs.3.rs-3465256/v1
Contreras-Villa, J., Martinez, G. R., Parra‐Ortega, I., Romo-Castillo, M., Cortés-Sarabia, K., Saldaña‐Ahuactzi, Z., Flores-Alanis, A., Aureoles-Romero, A., Salazar–García, M., González, J., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-12038-3
الشیمی, م. ل. (2021) · Al-Maǧallah Al-Miṣriyyaẗ Li-Buḥūṯ Al-Iʿlām · doi:10.21608/ejsc.2021.224632
Reporting of AstraZeneca studies may have caused vaccine reservations
Bignardi, G. E. (2021) · BMJ · doi:10.1136/bmj.n937
Meekhantong, P., Mahanonda, R., & Wisitrasameewong, W. (2022) · Chula Digiverse · doi:10.58837/chula.the.2022.276
Ratree, S., Assavapokee, N., Santibenchakul, S., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0342303
Pediatric Covid Vaccination: A Jab in Time Could Save Little Ones in their Prime!
Gopan, A. (2022) · Annals of Pediatric Gastroenterology & Hepatology · doi:10.5005/jp-journals-11009-0084
A new capless self-amplifying RNA
Arbuthnot, P. B., Bloom, K. M., & Ely, A. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.09.011
Kumari, A. L., & Rath, P. C. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05850-8
COVID-19: Reasons for Guarded Optimism
Snell, N. J. C. (2021) · Pharmaceutical Medicine · doi:10.1007/s40290-021-00381-0
COVID-19 in patients with inflammatory bowel diseases: Characteristics and guidelines
Taxonera, C., & López-García, O. N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18703-2.00022-0
Post-booster longitudinal plasma proteomic changes following BNT162b2 COVID-19 vaccination in Qatar
Bentebbal, S., Zaqout, A., Meqbel, B., Bensmail, I., Aldushain, A., de la Fuente, A., Thomas, R., Naik, A., Shaath, H., Al-Akl, N. S., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1762522
Bayesian uncertainty quantification to identify population level vaccine hesitancy behaviours
Warne, D. J., Varghese, A., Brewster, A., Browning, A. P., Krell, M. M., Drovandi, C., Hu, W., Mira, A., Mengersen, K. L., & Jenner, A. L. (2026) · PLoS ONE · doi:10.1371/journal.pone.0349499
Li, Q., Ling, Y., Chen, G., & Ye, S. (2024) · Medical Hypotheses · doi:10.1016/j.mehy.2024.111406
Rahman, S. A., Bommireddy, R., Routhu, N. K., Lai, L., Pack, C. D., Ramachandiran, S., Suthar, M. S., Reddy, S. J. C., Selvaraj, P., & Amara, R. R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.24.595657
Medical Interventions and Risk
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0009
Watanabe, K., Watanabe, C., Honma, T., Tian, Y., Kawashima, Y., Kawashita, N., Takagi, T., & Fukuzawa, K. (2021) · ChemRxiv · doi:10.26434/chemrxiv.14135138
Immune Responses to mRNA Vaccine
Exposito, J., Monge, C., Arruda, D. C., & Verrier, B. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch2
(2000) · Time to knit · doi:10.1016/s2211-9698(21)44374-8
Quantum AI in mRNA Vaccine Development
Fakhoury, N., & Roosan, D. (2026) · Springer eBooks · doi:10.1007/978-3-032-19536-4_7
Ethical and legal requirements for vaccination against COVID-19
Franc, A., & Bíba, V. (2022) · Česká a slovenská farmacie · doi:10.5817/csf2022-1-3
Review the safety and efficacy of vaccines under the condition of COVID-19 epidemic
Zhang, Q. (2022) · AIP conference proceedings · doi:10.1063/5.0094314
Augmenting the Cytotoxicity of Anticancer Peptide K6L9 by In Vitro-Synthesized mRNA
Njoka, M., Covarrubias‐Zambrano, O., Tripathi, A., Santana-Magal, N., Jeppson, J. D., Akhavan, D., Pyaram, K., Bossmann, S. H., & Kamath, D. V. (2026) · Applied Sciences · doi:10.3390/app16073288 · Cited by 1
Li, J., Pan, Y., Han, Y., Zhou, C., Zhao, L., & He, Y. O. (2026) · medRxiv · doi:10.64898/2026.07.02.26357163
Thanborisutkul, K., Kulalert, P., Methaset, K., Nanthapisal, S., Chunthatikul, T., Phangpanya, N., Charoenying, P., Atsawutmangkru, W., Srijaroen, S., Punyashthira, P., et al. (2025) · Vaccines · doi:10.3390/vaccines13030289 · Cited by 1
“Likewise, Baden et al. [7] conducted a randomized, observer-blinded, placebo-controlled trial for the efficacy and safety of the mRNA-1273 vaccine and showed that solicited local and systemic adverse events occurred more frequently in the mRNA-1273 group than in the placebo group.”
Siniscalchi, C., Imbalzano, E., Basaglia, M., Cerundolo, N., Meschi, T., Prati, B., Parise, A., Nouvenne, A., & Micco, P. D. (2026) · Vaccines · doi:10.3390/vaccines14070611
Gaikwad, A., Mehta, V., Shah, C., Agrawal, M., Shaik, R. A., Alharbi, M. B., Alrouji, M., Alhajlah, S., AlOmeir, O., Ahmad, R. K., et al. (2022) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.spl.577
Awakening Sleeping Beauties from articles on mRNA vaccines against COVID-19
Chaleplioglou, A., Selinopoulou, E., Kyprianos, K., & Koulouris, A. (2026) · Scientometrics · doi:10.1007/s11192-026-05598-x · Cited by 1
“The development and worldwide vaccination of human populations with the mRNA vaccines BNT162b2 by Pfizer-BioNTech (Polack et al., 2020) and mRNA-1273 by Moderna (Baden et al., 2021) represent disruptive applications of an existing, but not widely produced or tested, technology.”
Synthesis and optimization of ionizable lipids for RNA delivery
Wu, B., Lu, X., Padilla, M. S., Dharmesh, E., Xu, Y., Mitchell, M. J., & Han, X. (2026) · Chem · doi:10.1016/j.chempr.2026.103244 · Cited by 1
Langerhans cell–targeted mRNA delivery as a skin-based strategy
Caucheteux, S. M., & Piguet, V. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2026.04.028
An overview of the mRNA applications and their therapeutic functions in clinical development
Ramakrishnaiah, T. N., Srikar, K. S., Deb, A., Ahmed, K. S., Chandraghatgi, R. R., Sarin, Y., Roopini, K., & Rajashekara, S. (2026) · Next research. · doi:10.1016/j.nexres.2026.101413
Caractérisation des activités antivirales des anticorps anti-VIH-1 et anti-SARS-CoV-2
Dufloo, J. (2021) · theses.fr (ABES) · doi:10.70675/215798eaz7f82z4e57za8eazf4453d37b8c8
Introduction to RNAi therapeutics
Bunekar, N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45006-8.00013-6 · Cited by 1
DeDiego, M. L., Portilla, Y., López-García, D., Daviu, N., Vázquez-Utrilla, P., Gallo‐Córdova, Á., Morales, M. P., & Barber, D. F. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837672967-00330 · Cited by 1
Sood, S., Matar, M. M., Kim, J., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4576080
Ardyanto, T., Khariri, Agus, T. P., Handayani, S., & Soebandrio, A. (2024) · The Open Public Health Journal · doi:10.2174/0118749445337489240726050131
Sood, S., Matar, M. M., Kim, J., Kinsella, M. D., Rayavara, K., Signer, O., Henderson, J., Rogers, J., Chawla, B., Narváez, B., et al. (2023) · bioRxiv · doi:10.1101/2023.08.01.551509 · Cited by 3
Literature analysis of the efficacy of COVID-19 vaccinationsPreprint
Hulsen, T. (2022) · medRxiv · doi:10.1101/2022.12.24.22283835
Saithong, S., Prompetchara, E., Ketloy, C., Khawsang, C., Tharakhet, K., Kaewpang, P., Yostrerat, N., Wangsoontorn, P., Charsangbong, K., Lam, K., et al. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2686510
“20,21 This led to the fast expansion of mRNA technology to address infectious diseases, cancer, and various other applications, including HPV-related cancers.”
Long-term clinical outcomes and prognosis
Molinari, L. V., Ricci, F., Gallina, S., Fedorowski, A., & Chahal, C. A. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14001-3.00012-1
Viral Infections: Overview with a focus on Prevention of Transmission
Wong, S., Chiu, K. H., Yip, C. C., Chan, J. F., Hung, I. F., To, K. K., Cheng, V. C., & Yuen, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00208-8
Rocha, A., Milan, E. P., Caminha, R. O. D. C., et al. (2024) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v27i1.613_eng
Self-amplifying mRNA expression is governed by mitochondrial machinery and ACSL4Preprint
Tshering, L. F., Wang, C., Xiang, Q., Kundu, S., Solórzano, A., Chaparro‐Riggers, J. F., Lin, L., & Paksa, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.13.659366
Jamali, N., Salimi, A., Moghimipour, E., et al. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103486
Probing the conformational changes of in vivo overexpressed cell cycle regulator 6S ncRNA
Makraki, E., Miliara, S., Pagkalos, M., Kokkinidis, M., Mylonas, E., & Fadouloglou, V. E. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1219668
Management of Cancer During the COVID-19 Pandemic: The Rewritten Rules
Dosso, S. D., & Vannelli, A. (2021) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2021.09.043
Vaccin Moderna mRNA-1273 contre la Covid-19 : une aide à la décision
Conseil Scientifique du, C. N. G. E. (2021) · EXERCER · doi:10.56746/exercer.2021.175.320
Maharlouei, N., Zarei, L., Moradi, N., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-645571/v1
Covid Vaccine Risk Stratification
Standaert, L., Munasinghe, T., Jang, D., et al. (2021) · IEEE International Conference on Big Data (BigData) · doi:10.1109/bigdata52589.2021.9671601
Louten, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90565-7.00014-9
Dadabhai, S. S., Samandari, T., Zhang, B., Hudson, A., Mkhize, N. N., Tapley, A., Andriesen, J. G., Moore, P., Chirenje, Z. M., Elyanu, P., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10935317/v1
“Monovalent vaccines targeting the ancestral WA1 SARS-CoV-2 strain were deployed worldwide after trials demonstrated >94% efficacy against symptomatic disease, and up to 100% efficacy in preventing severe disease and death after two doses three to four weeks apart 1,2 .”
Self-citationLe, D. T. H., Yang, C., Zhang, Y., Zhao, G., Seow, B. Y. L., Zhao, X., Balakrishnan, N., Bae, K. H., Hui, J. H. P., & Yang, Y. Y. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115136
COVID-19 vaccine adverse events in indigenous communities in Northwest Territories, Canada
Omidimorad, A., Kolahdooz, F., Wagg, A., Gotay, C. C., DeLancey, D., Kandola, K., Corriveau, A., Irlbacher‐Fox, S., Conter, H. J., & Sharma, S. (2026) · Vaccine X · doi:10.1016/j.jvacx.2026.100812
Gasmi, A., Semenova, Y. M., Noor, S., Nehaoua, A., Malek, R., Malek, H., & Bjørklund, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95648-2.00005-8
Dulipsingh, L., Lang, M., Diffenderfer, M. R., Cook, L., Puff, J., Diaz, L., He, L., & Schaefer, E. J. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4156654
Paduch, J., Syrowatko, A., & Żołnierczuk, M. (2021) · Journal of Education Health and Sport · doi:10.12775/jehs.2021.11.10.007
Yu, T., Wang, Y., Kong, Y., Wang, J., Hong, Y., Wang, Y., Hu, F., Zhu, Z., & Yuan, H. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501497 · Cited by 3
Klegerman, M. E., Cirillo, J. D., & McPherson, D. D. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.26.441517
COVID-19 and Transplant Patients: Challenges, Risks, and Evolving Strategies
Campise, M. (2025) · Vaccines · doi:10.3390/vaccines13030318
“Soon after, other vaccines, including AstraZeneca, Johnson & Johnson, and Sinopharm, followed, providing hope for mass immunization and pandemic control [10,11].”
Zou, Z., Fairley, C. K., Shen, M.-W., et al. (2021) · medRxiv · doi:10.1101/2021.07.06.21260055 · Cited by 1
Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccinationPreprint
Sato, Y., Uwamino, Y., Nagashima, K., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1822996/v1
Hale, K. L. E., McCarthy, H. O., & McLaughlin, M. (2026) · Chemistry - A European Journal · doi:10.1002/chem.202502321
“Following the successful introduction of the Pfizer/ BioNTech [ 12–14 ] and Moderna [ 15 ] COVID19 mRNA vaccines in 2020, there has been growing interest in improving the technologies that are currently available for in vitro mRNA manufacture,”
InfluentialCOVID-19 Vaccine–Associated Myocarditis Considerations for Competitive Athletes
Tso, J., & Kim, J. H. (2023) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-023-01009-z
Bhattacharya, D., Kanungo, S., Palo, S. K., Kshatri, J. S., Pattnaik, M., Ghosal, S., Mohapatra, P., Rao, C. M., Sahoo, A., Mishra, R. P., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1041586
EMJ COVID-19 monthly top five (June 2021)
Chatha, R., Reed, M., Jennings, H., McClatchey, A., Shahin, A., Williamson, C., McGowan, B., & Oliver, G. J. (2021) · Emergency Medicine Journal · doi:10.1136/emermed-2021-211796
Historical Development Process of mRNA Vaccines and SARS-CoV-2 Pandemic
GÜNEŞ, N., & Karabulut, Ş. (2021) · Journal of Molecular Virology and Immunology · doi:10.46683/jmvi.2020.14
Immunization against COVID-19: A Comprehensive Review on the Leading Vaccines
Srinivasan, A., Rajesh, V., Thamilvanan, D., Ganesh, S. K., & Chandrasekaran, S. D. (2023) · Coronaviruses · doi:10.2174/0126667975285709231219080802
Potential socioeconomic approaches for commercialized antimicrobial applications
Jangra, P., Negi, G., Sharma, A., & Parveen, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99148-3.00008-x
Next‐Generation Bio‐Reducible Lipids Enable Enhanced Vaccine Efficacy in Malaria and Primate Models
Coen, R. D., Kasmi, S., Dumbre, S. G., Baekens, L., Seynaeve, E., den Hauwe, L. V., Cantini, N., Garantoudi, A., Madeira, F. B., Marrot, A., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202509838 · Cited by 4
He, H., Jin, X., Li, Z., et al. (2025) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/apjtm.apjtm_398_24
Ansari, A. I., Abbas, M., Rizvi, A. A., Afreen, S., Verma, S., Mehdi, M., Verma, S., & Mahdi, F. (2024) · Coronaviruses · doi:10.2174/0126667975285693240427073251
Amani, E., Otroshi, B., Tabatabaie, M., Moslemi, A., & Shabani, S. (2025) · The Clinical Respiratory Journal · doi:10.1111/crj.70127 · Cited by 1
Hoff, F. W., Goksu, S. Y., Premnath, N., Patel, P. A., Ikpefan, R., Kaur, G., Vusirikala, M., Bat, T., Chen, W., Geethakumari, P. R., et al. (2023) · Acta Medica Academica · doi:10.5644/ama2006-124.399
Mechanism of modified mRNA structure in COVID-19 vaccines for inducing neutralizing antibodies
Zanjabila, S., & Dewi, B. E. (2024) · Acta Biochimica Indonesiana · doi:10.32889/actabioina.121
Rodriguez‐Watson, C., Ware, K., Eckert, J. C., et al. (2026) · Journal of Women s Health · doi:10.1177/15409996261444636
NEURO-COVAX: An Italian Population-Based Study of Neurological Complications After COVID-19 VaccinesPreprint
Salsone, M., Signorelli, C., Oldani, A., Patone, M., Alberti, V. F., Castronovo, V., Mazzitelli, S., Minerva, M., & Ferini‐Strambi, L. (2022) · Research Square · doi:10.21203/rs.3.rs-1978727/v1
The Nature of Chronic Diseases and Mental Disorders
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0006
Heterologous Vaccination for Preparing COVID-19 Pandemic
Kim, T. H. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.6.450
Age‐related differences in mRNA vaccine immunogenicity and adjuvancy
Chinni, S. S., Trollope, G. S., Leung, P., McQualter, J. L., Tan, C. W., Wang, L., Lim, L., Wheatley, A. K., Juno, J. A., Kent, S. J., et al. (2026) · Immunology and Cell Biology · doi:10.1111/imcb.70102
Effectiveness of COVID-19 Vaccine in Prevention of Mortality Among Moderate-Severe Cases
Yadav, A. K., Vasisht, K., Ghosh, S., & Bobdey, S. (2022) · Medical Journal of Dr D Y Patil Vidyapeeth · doi:10.4103/mjdrdypu.mjdrdypu_195_22
Evolution of our understanding of MS-COVID-19 interactions and concerns for vaccination
Podury, S., Khan, E. I., Tandon, M., et al. (2021) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2021.05.063
Hong, T., Masuda, K., Nakashima, Y., Li, S., Chen, P., Hu, G., Igarashi, K., Kimura, A., Fujita, K., Umezu, T., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114274 · Cited by 2
Orno, T. G., & Yuniarty, T. (2023) · JURNAL PENGABDIAN KEPADA MASYARAKAT SISTHANA · doi:10.55606/pkmsisthana.v5i1.226
Wu, H. H. L. (2024) · Indian Journal of Kidney Diseases · doi:10.4103/ijkd.ijkd_29_24
Pericarditis and Myocarditis after mRNA-based COVID-19 Vaccination
Hong, R., Yap, J. J. L., & Yeo, K. K. (2022) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2021.26
Pneumonies virales épidémiques – Pneumonie à SARS-CoV-2 : où en sommes-nous ?
Delomez, J., Vabret, A., Andréjak, C., & Schlemmer, F. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00059-8
High-tech Drugs Against COVID-19
Moingeon, P. E. (2025) · Springer eBooks · doi:10.1007/978-3-031-91668-7_1
Adverse reactions to mRNA COVID-19 vaccine in people with allergies in Japan
Shoji, N., Ito, S., Nojiri, S., Urasaki, W., Nara, T., Okuzawa, A., & Tobita, M. (2024) · Global Health & Medicine · doi:10.35772/ghm.2024.01053
Rahemtoola, M. S., & Pillai, A. (2025) · Cureus · doi:10.7759/cureus.91816
“In fact, trials evaluating Pfizer/BioNTech demonstrated a 95% efficacy at preventing severe COVID-19 [28,29].”
InfluentialPeña, Á., Broset, E., Lucía, E. G., García-Latorre, L., Navarro, V., Matute, C., Gallego-Lleyda, A., Alejo, T., Romanos, E., García, A., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040472
Hartley, G. E., Edwards, E. S. J., Varese, N. P., Boo, I., Aui, P. M., Bornheimer, S. J., Hogarth, P. M., Drummer, H. E., O’Hehir, R. E., & van Zelm, M. C. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.03.502703
Older subjects and immunogenicity of mRNA COVID-19 vaccines
Seiffert, P., & Religa, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95648-2.00051-4
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.